非HDL-C与动脉粥样硬化性心血管病

Non-HDL-C and atherosclerotic cardiovascular disease

动脉粥样硬化性心血管病(ASCVD)是一种脂质代谢紊乱与炎症性血管疾病,他汀治疗LDL-C达标后仍存在心血管风险。越来越多的证据表明,非HDL-C对于ASCVD的风险预测作用强于LDL-C。大部分ASCVD患者需要最大可耐受剂量的他汀治疗,部分患者需要在他汀基础上联用非他汀药物治疗,以实现非HDL-C的达标,贝特类药物是与他汀联合治疗的合适选择。

Atherosclerotic cardiovascular diseases(ASCVD)is a lipid metabolic disorder and inflammatory vascular disease.Residual cardiovascular risk remained although the LDL-C goal was achieved with statin therapy.Increasing evidence showed that,compared with LDL-C,non-HDL-C was a better predictor of ASCVD risk.Most patients with ASCVD require the highest tolerable dose of statin therapy,while part of them need to add non-statin therapy to achieve the non-HDL-C goal.Fibrates is an appropriate choice for combination therapy.